Compare Fubotv Inc (FUBO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Eli Lilly And Co — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Eli Lilly And Co trades at $1,173.98 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 1019.6× Fubotv Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Eli Lilly And Co for 93 Days on average.
| FUBO | LLY | |
|---|---|---|
Market Cap | $1.02B | $1.04T |
Volume | 978,631 | 3,064,878 |
Sector | Media | Health |
52-Week High | $48.96 | $1.28K |
52-Week Low | $8.09 | $799.57 |
Typical Hold Time | 35 Days | 93 Days |
Enterprise Value | $1.19B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.03, down 2.38% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M in 2025, representing a significant turnaround from previous losses. Recent developments include new sports streaming agreements with NHL teams and expanded partnerships with The Athletic, positioning the company for continued subscriber growth.
FUBO presents a compelling turnaround story with deep valuation discounts (P/E 2.43, P/S 0.19) and analyst consensus target of $63.38 suggesting 600%+ upside. However, risks include persistent cash flow challenges, high debt levels, and intense streaming competition. The Disney partnership and sports content expansion provide catalysts, but execution risk remains elevated given the company's history of losses.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
